Overview

Triple-Negative Breast Cancer Treatment Market is forecasted to value over CAGR of over 5.3% from 2022 to 2028.

Triple-negative breast cancer is a type of cancer that does not have any receptors for hormones progesterone and estrogen. Triple-negative breast cancer does not respond to hormonal therapy and requires combines surgery.

Based on drug type the market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin/carboplatin, and others. Doxorubicin is a chemotherapy drug used to treat acute lymphocytic leukemia, breast cancer, and bladder cancer. It slows down the growth of the cancer cells. Paclitaxel injection is used in the treatment of stomach cancer, prostate cancer, testicular cancer, and breast cancer. Doxorubicin can also interact with cyclophosphamide and paclitaxel. Based on the distribution channel, the market is bifurcated into hospital pharmacies and speciality cancer clinics. Speciality cancer clinics are the biggest end users owing to the easy availability of facilities.

The growing need for effective treatment against breast cancer is driving the growth of the market. A gradual increase in research and development alongside the adoption of new treatment types against cancer is expected to spur the size of the market. 

Collaborations among prominent players in development and research of innovative and new drug are stimulating the size of the market. In addition, the robust pipeline of drugs in clinical development to diagnose triple-negative breast cancer treatment is also fueling the growth of the market. A huge trend spotted in the triple-negative breast cancer treatment is the evolution of nanotechnology. Nanotechnology has emerged as an efficient tool in the clinical management of triple-negative breast cancer.

North America currently holds a vast share of the market. The presence of prominent players alongside advanced healthcare infrastructure has expanded the size of the market. The Asia Pacific and Latin America regions have established vast potential opportunistic space for manufacturers thanks to an increase in treatment rate and rising prevalence of triple-negative breast. Increasing healthcare infrastructure in countries like India and China is expected to boost the growth of the market in the region in the coming years. 

Established players of the market are:
AstraZeneca PLC, Pfizer, Inc. , F. Hoffman - La Roche Ltd. , Bristol-Myers Squibb Company, Novartis AG, Mylan N.V. , Eli Lilly and Company, Celgene Corporation, Sanofi S.A., and Johnson & Johnson Services, Inc., among others.

Triple-Negative Breast Cancer Treatment Market Segmentation: 
By Drug Type
•    Doxorubicin
•    Cyclophosphamide
•    Paclitaxel
•    Docetaxel 
•    Cisplatin/Carboplatin 
•    Others

By Distribution Channel 
•    Hospital Pharmacies
•    Specialty Cancer Clinics

By Region
•    Europe  
•    North America  
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

 Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major market share  
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants   

FutureWise Takeaways: 
•    Growth prospects  
•    SWOT analysis 
•    Key trends 
•    Key data points affecting market growth  

Objectives of the Study: 
•     To provide with an exhaustive analysis on Global Triple-Negative Breast Cancer Treatment Market by Drug Type, by Distribution Channel, by Region 
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 
•    To evaluate and forecast micro-markets and the overall market  
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions 
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Flexible Delivery Model:
•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com 

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
    2.1. Research Data 
         2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
                2.1.2.1. Key Data from Primary Sources
    2.2. Market Size Estimation 
    2.3. Market Breakdown and Data Triangulation 
    2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Triple Negative Breast Cancer Treatment Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Type Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Triple Negative Breast Cancer Treatment Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Triple Negative Breast Cancer Treatment Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Type Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Type Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Triple Negative Breast Cancer Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Doxorubicin
   7.2. Cyclophosphamide
   7.3. Paclitaxel
   7.4. Docetaxel
   7.5. Cisplatin/Carboplatin
   7.6. Others

8. Triple Negative Breast Cancer Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Hospital Pharmacies
   8.2. Specialty Cancer Clinics

9. North America Triple Negative Breast Cancer Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. U.S.A
        9.2.2. Canada
        9.2.3. Mexico
   9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Triple Negative Breast Cancer Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Brazil
          10.2.2. Venezuela
          10.2.3. Argentina
          10.2.4. Rest of Latin America
    10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Triple Negative Breast Cancer Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Germany
          11.2.2. U.K         
          11.2.3. France
          11.2.4. Italy
          11.2.5. Spain
          11.2.6. Russia
          11.2.7. Poland
          11.2.8. Rest of Europe
    11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Triple Negative Breast Cancer Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Japan
          12.2.2. China
          12.2.3. India
          12.2.4. Australia and New Zealand
          12.2.5. ASEAN
          12.2.6. Rest of Asia Pacific
    12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. GCC
          13.2.2. Israel
          13.2.3. South Africa
          13.2.4. Rest of MEA
    13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    15.1. AstraZeneca PLC
          15.1.1. Company Overview
          15.1.2. Product Portfolio
          15.1.3. SWOT Analysis
          15.1.4. Financial Overview
          15.1.5. Strategic Overview
    15.2. Pfizer, Inc.
          15.2.1. Company Overview
          15.2.2. Product Portfolio
          15.2.3. SWOT Analysis
          15.2.4. Financial Overview
          15.2.5. Strategic Overview                         
    15.3. F. Hoffman - La Roche Ltd.
          15.3.1. Company Overview
          15.3.2. Product Portfolio
          15.3.3. SWOT Analysis
          15.3.4. Financial Overview
          15.3.5. Strategic Overview
    15.4. Bristol-Myers Squibb Company
          15.4.1. Company Overview
          15.4.2. Product Portfolio
          15.4.3. SWOT Analysis
          15.4.4. Financial Overview
          15.4.5. Strategic Overview
    15.5. Novartis AG
          15.5.1. Company Overview
          15.5.2. Product Portfolio
          15.5.3. SWOT Analysis
          15.5.4. Financial Overview
          15.5.5. Strategic Overview          
    15.6. Mylan N.V.
          15.6.1. Company Overview
          15.6.2. Product Portfolio
          15.6.3. SWOT Analysis
          15.6.4. Financial Overview
          15.6.5. Strategic Overview      
    15.7. Eli Lilly and Company
          15.7.1. Company Overview
          15.7.2. Product Portfolio
          15.7.3. SWOT Analysis
          15.7.4. Financial Overview
          15.7.5. Strategic Overview
    15.8. Celgene Corporation
          15.8.1. Company Overview
          15.8.2. Product Portfolio
          15.8.3. SWOT Analysis
          15.8.4. Financial Overview
          15.8.5. Strategic Overview 
    15.9. Sanofi S.A
          15.9.1. Company Overview
          15.9.2. Product Portfolio
          15.9.3. SWOT Analysis
          15.9.4. Financial Overview
          15.9.5. Strategic Overview 
    15.10.Johnson & Johnson Services, Inc.       
          15.10.1. Company Overview
          15.10.2. Product Portfolio
          15.10.3. SWOT Analysis
          15.10.4. Financial Overview
          15.10.5. Strategic Overview 

16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures